Should we avoid heparin based anticoagulants in “COVID-19 infection-vaccination related thrombosis”? Insights from the HIT like syndrome observed with infected cases.
preprint
OA: gold
CC-BY-4.0
Abstract
Background: Recent reports of the prothrombotic states announced in the recipients of the ChAdOx vaccine, similar to HIT sounded alarm bells internationally.The sole outcome parameter of this systematic review was to detect similar cases of Prothrombotic state in COVID-19 infected patients Method: ology: Embase, Medline and the Cochrane Central Register were used to search for specic keywords such as “COVID-19” OR “SARS-CoV-2” AND “Heparin induced thrombocytopenia” for relevant publications up to 1 st of April 2021. The systematic review was performed using PRISMA protocol. Results: : Nine cases reports/series have been identified including 18 cases, venous thrombosis was the commonest type of observed thrombosis accounting for 72 % of cases, the mean age of cases was 57±4. Conclusion: Similar episodes of HIT were detailed in several case reports of COVID patients. This suggests a common pathogenesis and warrants a screening of all COVID-19 patients presenting with thrombo-embolism using anti-PF4 antibodies and using non heparin based anticoagulants for their management.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-4.0